OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
FDA Approves Sotorasib & Panitumumab Combination for KRAS G12C-Mutated Metastatic Colorectal Cancer

FDA Approves Sotorasib & Panitumumab Combination for KRAS G12C-Mutated Metastatic Colorectal Cancer

by FDA Approval | 17 January 2025 | Gastrointestinal

On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved the combination of sotorasib and panitumumab for treating adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC). This approval applies to patients who have undergone prior...
HER2 As A Target For Gastrointestinal Tumors

HER2 As A Target For Gastrointestinal Tumors

by Florian Lordick | 21 August 2024 | Gastrointestinal

Clinically relevant HER2 expression is found in some gastrointestinal tumors, such as carcinomas of the stomach and colon, which makes therapeutic targeting with proven and new substances possible. In the group of predictive markers evaluated in gastric cancer and...
EU to Approve Toripalimab for Advanced Head & Neck, & Zolbetuximab in GEJ cancer

EU to Approve Toripalimab for Advanced Head & Neck, & Zolbetuximab in GEJ cancer

by EMA Approval | 31 July 2024 | Gastrointestinal

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently recommended the approval of several new treatments for advanced cancers, including toripalimab-tpzi for nasopharyngeal carcinoma (NPC) and esophageal squamous cell...
Swissmedic Approves New Treatments for Gastric and Biliary Cancers

Swissmedic Approves New Treatments for Gastric and Biliary Cancers

by Swiss Approval | 25 June 2024 | Gastrointestinal

The Swissmedic has recently approved several new treatment options for gastric and biliary cancers, marking a substantial advancement in oncological care for patients with these challenging conditions.   Trastuzumab Deruxtecan Trastuzumab deruxtecan has been...

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}